{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Description of Change', 'Brief Rationale', 'Section # and Name', 'Cemiplimab Extension Phase (new', 'section)', 'Section 15 Protocol Amendments', 'Added language to remove', 'Based on limited data, the', 'Section 7.1.7 Note Regarding', 'option for retreatment upon', 'benefit of retreating patients', 'IDMC Interim Analysis 2 (new', 'disease progression for', 'with cemiplimab after', 'section)', 'patients entering the', 'progression on cemiplimab', 'cemiplimab Extension Phase.', 'during the follow-up phase', \"can't be confirmed.\", 'Added language to remove', 'This is due to the observed', 'Section 7.1.7 Note Regarding', 'follow-up visits for patients', 'superiority of OS in patients', 'IDMC Interim Analysis 2 (new', 'entering the cemiplimab', 'receiving cemiplimab as', 'section)', 'Extension Phase.', 'compared to IC', 'chemotherapy at the second', 'interim analysis.', 'Cemiplimab continues to', 'demonstrate a safety profile', 'consistent in class.', 'MedDRA Dictionary-Derived', 'The list was updated since', 'Appendix 3 MedDRA', 'Preferred Terms for Potential', 'the last amendment.', 'Dictionary-Derived Preferred Terms', 'immune-related adverse events', 'for Potential irAEs', '(irAEs) list updated as per', 'MedDRA version 23.0.', 'Amendment 6', 'Change and Rationale for Change', 'Sections Changed', 'Added European Network for Gynaecological', 'Protocol Number', 'Oncological Trial groups (ENGOT) number to', 'Protocol Version', 'Protocol Number and Protocol Version.', 'Added 2 interim analyses to provide early', 'Clinical Study Protocol Synopsis: Study', 'efficacy assessment in this unmet-need', 'Design, Population, Statistical Plan', 'population, and increased sample size to maintain', 'Section 3.2.1 Rationale for Patient', '90% power with 2 interim analyses.', 'Population and Study Design', 'Interim efficacy analyses will be reviewed by', 'Section 5.1 Study Description and', 'Independent Data Monitoring Committee', 'Duration', '(IDMC).', 'Regeneron Pharmaceuticals, Inc.', 'Page 4 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Change and Rationale for Change', 'Sections Changed', 'Figure 2 Study Design Schematic', 'Section 5.1.2 End of Study Definition', 'Section 5.2 Planned Interim Analysis', 'Section 5.3.1. Independent Data', 'Monitoring Committee', 'Section 6.1 Number of Patients Planned', 'Section 7.1.5 Footnotes for the Schedule', 'of Events Table for Post-Treatment', 'Follow-up, footnote #2', 'Section 8.8 Method of Treatment', 'Assignment', 'Section 10.2 Justification of Sample Size', 'Section 10.4.5.1 Primary Efficacy', 'Analysis', 'Section 10.5 Interim Analysis', 'Table 15 Alpha Spending in Group', 'Sequential Design Using Lan-DeMets', \"(O'Brien Fleming) Spending Function\", 'Section 10.6 Additional Statistical Data', 'Handling Conventions', 'Added language to meet a requirement under the', 'Section 5.4 Study Conduct in Response to', 'guidance that has come out in the', 'COVID-19 (new)', 'to address considerations related to', 'Section 7.1.1 COVID-19 Adaptation', 'conduct of a study during the COVID-19', '(new)', 'pandemic, including statistical analysis language.', 'Section 10 Statistical Plan', 'Corrected typo regarding lymph nodes to have', 'Section 6.2.1 Inclusion Criteria, #3', 'Inclusion Criteria #3 consistent with Appendix 1.', 'Changed >15 mmto >15 mm.', 'Added language to clarify that peripheral blood', 'Section 7.1.5 Footnotes for the Schedule', 'mononuclear cell (PBMC) collection is optional', 'of Events Table for Post-Treatment', 'and will only be done for patients receiving', 'Follow-up, footnote #6', 'cemiplimab and who have signed the', 'PBMC consent.', 'Corrected typo in Appendix 1 to make consistent', 'Appendix 1.RESPONSE EVALUATION', 'with Response Evaluation Criteria in Solid', 'CRITERIA IN SOLID TUMORS:', 'Tumors (RECIST) guidelines.', 'RECIST GUIDELINE (VERSION 1.1)', 'Regeneron Pharmaceuticals, Inc.', 'Page 5 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}